Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Hirohisa, Yoshizawa"'
Autor:
Satoshi Watanabe, Takeshi Ota, Masachika Hayashi, Hiroyuki Ishikawa, Aya Otsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Takao Miyabayashi, Satoru Miura, Hiroshi Tanaka, Tetsuya Abe, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Toshiaki Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Abstract Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an
Externí odkaz:
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
Autor:
Toshiya Fujisaki, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Yusuke Sato, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Naoya Matsumoto, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Masachika Hayashi, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesAlthough immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients, ICIs sometimes cause various types of immune-related adverse events (irAEs), which lead t
Externí odkaz:
https://doaj.org/article/ecc089bdf85d4930b1e2d948173bc025
Autor:
Yu Saida, Satoshi Watanabe, Tetsuya Abe, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Kenichi Koyama, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Takashi Ishida, Hiroki Tsukada, Masato Makino, Akira Iwashima, Kazuhiro Sato, Naoya Matsumoto, Hirohisa Yoshizawa, Toshiaki Kikuchi
Publikováno v:
Thoracic Cancer, Vol 10, Iss 11, Pp 2106-2116 (2019)
Background Although the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has been demonstrated, their efficacy in EGFR‐mutant NSCLCs with c
Externí odkaz:
https://doaj.org/article/4c3c0980a21a4b178a904cf7dd6b0608
Autor:
Satoshi, Shoji, Satoru, Miura, Satoshi, Watanabe, Aya, Ohtsubo, Koichiro, Nozaki, Yu, Saida, Kosuke, Ichikawa, Rie, Kondo, Tomohiro, Tanaka, Kenichi, Koyama, Hiroshi, Tanaka, Masaaki, Okajima, Tetsuya, Abe, Takeshi, Ota, Takashi, Ishida, Masato, Makino, Akira, Iwashima, Kazuhiro, Sato, Naoya, Matsumoto, Hirohisa, Yoshizawa, Toshiaki, Kikuchi
Publikováno v:
Translational Lung Cancer Research. 11:1359-1368
This multicenter, open-label, single-arm phase II study [Niigata Lung Cancer Treatment Group (NLCTG) 1302] was conducted to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy for previously treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2edbbf63498c552456847e7013c68d58
https://doi.org/10.21037/tlcr-22-89
https://doi.org/10.21037/tlcr-22-89
Autor:
Tomohiro Tanaka, Satoshi Watanabe, Miho Takahashi, Ko Sato, Yu Saida, Junko Baba, Masashi Arita, Miyuki Sato, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Nobumasa Aoki, Yasuyoshi Ohshima, Takuro Sakagami, Tetsuya Abe, Hiroshi Moro, Toshiyuki Koya, Junta Tanaka, Hiroshi Kagamu, Hirohisa Yoshizawa, Toshiaki Kikuchi
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183976 (2017)
The adoptive transfer of effector T cells combined with lymphodepletion has demonstrated promising antitumor effects in mice and humans, although the availability of tumor-specific T cells is limited. We and others have also demonstrated that the tra
Externí odkaz:
https://doaj.org/article/2449b99e102e40c89d91867d26d62514
Autor:
Hirohisa Yoshizawa, Naoya Matsumoto, Hiroshi Tanaka, Satoru Miura, Kazuhiko Ito, Masaaki Okajima, Akira Iwashima, Kazuhiro Sato, Takashi Ishida, Masato Makino, Kosuke Ichikawa, Tetsuya Abe, Toshiaki Kikuchi, Satoshi Watanabe
Publikováno v:
Transl Lung Cancer Res
Background Afatinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Many patients treated with afatinib experience skin or gastrointestinal toxicity. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f07199b680be61b02d6921574a8d79b
https://doi.org/10.21037/tlcr-20-649
https://doi.org/10.21037/tlcr-20-649
Autor:
Rie Kondo, Satoru Miura, Akira Iwashima, Hiroyuki Ishikawa, Aya Otsubo, Masaaki Okajima, Satoshi Shoji, Satoshi Watanabe, Hiroshi Tanaka, Kazuhiro Sato, Kosuke Ichikawa, Tetsuya Abe, Takashi Ishida, Takao Miyabayashi, Hirohisa Yoshizawa, Masachika Hayashi, Koichiro Nozaki, Masaki Terada, Takeshi Ota, Toshiaki Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Cancer Medicine
Cancer Medicine
Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an enhanceme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7f858e17034989d1f0ff78120f0c62a
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
Autor:
Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto, Jun Koshio, Akira Ishida, Tetsuya Abe, Daisuke Ishikawa, Tomohiro Tanaka, Ami Aoki, Tomosue Kajiwara, Kenichi Koyama, Satoru Miura, Yuka Goto, Tomoki Sekiya, Ryo Suzuki, Kohei Kushiro, Toshiya Fujisaki, Naohiro Yanagimura, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Yu Saida, Hirohisa Yoshizawa, Kazuto Nishio, Toshiaki Kikuchi
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 204
Anaplastic lymphoma kinase (ALK)-positive lung cancer is a rare cancer that occurs in approximately 5% of non-small-cell lung cancer (NSCLCs) patients. Despite the excellent efficacy of ALK-tyrosine kinase inhibitor in ALK-positive NSCLCs, most patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b910a50315470b0005c2aed738770fcf
https://doi.org/10.3390/cancers15010204
https://doi.org/10.3390/cancers15010204
Autor:
Koh Nakata, Ichiei Narita, Hiroshi Kagamu, Satoshi Watanabe, Takao Miyabayashi, Junko Baba, Takeshi Ota, Hiroshi Tanaka, Koki Matsuyama, Hirohisa Yoshizawa
Publikováno v:
Middle East Journal of Cancer, Vol 2, Iss 1, Pp 9-18 (2011)
Background: Nonmyeloablative chemotherapy followed by adoptiveimmunotherapy is an attractive strategy for depleting regulatory T cells in the host. However, its efficacy is transient. Here, we aim to investigate whether cyclic chemoimmunotherapy has
Externí odkaz:
https://doaj.org/article/3cd61f1a950243f8b1ee120e2b73f224
Autor:
Hiroshi Tanaka, Yusuke Sato, Masaaki Okajima, Koichiro Nozaki, Takeshi Ota, Toshiya Fujisaki, Masaki Terada, Toshiaki Kikuchi, Naoya Matsumoto, Satoshi Watanabe, Aya Ohtsubo, Rie Kondo, Takashi Ishida, Satoshi Shoji, Satoru Miura, Akira Iwashima, Masachika Hayashi, Takao Miyabayashi, Miho Takahashi, Kohei Kushiro, Satoshi Hokari, Hirohisa Yoshizawa, Toshiyuki Koya, Kosuke Ichikawa, Nobumasa Aoki, Tetsuya Abe, Kazuhiro Sato, Yasuyoshi Ohshima
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
ObjectivesAlthough immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients, ICIs sometimes cause various types of immune-related adverse events (irAEs), which lead t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773d59de452ef420169ce75500dec6f1
https://www.frontiersin.org/articles/10.3389/fonc.2021.704475/full
https://www.frontiersin.org/articles/10.3389/fonc.2021.704475/full